Zhitong Finance App News, China Traditional Chinese Medicine (00570) issued an announcement that the State Drug Administration accepted the registration and marketing application for the Class 1.1 innovative traditional Chinese medicine Yuzhida tablets from Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. (Tongjitang Pharmaceutical), a subsidiary of the group. After completing a series of work procedures such as technical review, on-site inspection, and sample inspection by the State Drug Administration, Tongjitang Pharmaceutical's Class 1.1 innovative traditional Chinese medicine anti-spleen and antidepressant tablets (that is, “Yu Shuda tablets” as previously announced, the standardized generic name approved by the State Drug Administration) have been approved for marketing, and the drug marketing license holder is Tongjitang Pharmaceuticals.

Spleen relief tablets have the effect of awakening the spleen and relieving depression. They are used for mild to moderate depression. The symptoms are depression, depression, lack of expression, fatigue, insomnia, excessive dreaming, lack of energy and sluggishness, poor appetite, heavy head and body congestion, sticky mouth, dark face, pale moss or gray, smooth pulse.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.